HomeAI · summaries
Storia in 4 fonti
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survival
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer
CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to…
- ·
morningstar.com
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long…
- ·
medpagetoday.com
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survival
- ·
medicalxpress.com
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone…